Alx oncology's evorpacept receives fast track designation from fda as first-line treatment for head and neck squamous cell carcinoma

South san francisco, calif., aug. 01, 2022 (globe newswire) -- alx oncology holdings inc., (“alx oncology”) (nasdaq: alxo) a clinical-stage immuno-oncology company developing therapies that block the cd47 checkpoint pathway, today announced that the u.s. food and drug administration (“fda”) has granted fast track designation to evorpacept, a next generation cd47 blocker, in combination with keytruda® (pembrolizumab), merck's anti-pd-1 therapy, for the first-line treatment of adult patients with pd-l1 positive advanced head and neck squamous cell carcinoma (“hnscc”).
ALXO Ratings Summary
ALXO Quant Ranking